Premium
Imaging apolipoprotein AI in vivo
Author(s) -
Sriram Renuka,
Lagerstedt Jens O.,
Petrlova Jitka,
Samardzic Haris,
Kreutzer Ulrike,
Xie Hongtao,
Kaysen George A.,
Desreux Jean F.,
Tho David,
Jacques Vincent,
Van Loan Martha,
Rutledge John C.,
Oda Michael N.,
Voss John C.,
Jue Thomas
Publication year - 2011
Publication title -
nmr in biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 114
eISSN - 1099-1492
pISSN - 0952-3480
DOI - 10.1002/nbm.1650
Subject(s) - in vivo , biodistribution , lipoprotein , apolipoprotein b , gadolinium , chemistry , cysteine , mri contrast agent , cholesterol , medicine , biochemistry , in vitro , biology , microbiology and biotechnology , organic chemistry , enzyme
Coronary disease risk increases inversely with high‐density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo , however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS‐ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium‐diethylenetriaminepentaacetic acid‐bismethylamide (GdDTPA‐BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo . Copyright © 2011 John Wiley & Sons, Ltd.